Search Weight Loss Topics:

Page 52«..1020..51525354..6070..»

Home » Testosterone » Page 52

An excerpt from Abigail Shriers Irreversible Damage: The Transgender Craze Seducing Our Daughters, published June 30.

Alex Bertie, a British female-to-male YouTuber, and perhaps the most popular (he has over three hundred thousand subscribers), vlogged about his first year on testosterone: This is the day I never thought would come, enthused boyishly adorable, scruffy-jawed Alex. Im officially one year on testosterone. Before hormones, I was struggling with severe self-hate, jealousy, and just the urge to isolate myself from everybody Now, a year after starting hormones, I couldnt be happier. The changes from testosterone really have improved my quality of life and just made such a difference in shaping my future.

His voice has deepened. Hes sprouted body hair and a beard. His shoulders are broader, his arms are bigger, his jaw squarer. His fat is redistributed (less in the thighs and hips). And perhaps most thrilling of all: his periodgone. Luckily, after two months on T, mine completely stopped, thank God. Within the last year, I also had top surgery. Now this is its own thing. I can make a million videos about how much top surgery has helped me. But hand-in-hand with hormones, this seriously just wiped away my dysphoria. So all in all, testosterone has been pretty amazing.

Because of the mercurial and subjective nature of the trans identity, tension naturally arises about who is really transor trans enough. For that reason, testosterone can be an important means of establishing ones bona fides. As Chase Ross puts it in his Trans 101 video series, testosterone brings more legitimacy to your transition. But then, Chase rushes to reassure: the legitimacy of your transition is how you define your transition.

Not every trans vlogger shares Chases moderation.

Male-to-female Instagram guru Kaylee Korol, a blue-eyed and blue-haired waif who seems like an average teenage girl, offers this trans tip: [Y]ou dont need to be a hundred percent sure youre trans to try hormones, you dont, Kaylee assures viewers. You can try hormones for three months. After three months there starts to be permanent effects, but until around then you can just try hormones and see how you feel. Its great, its that easy. Hormones arent as scary as everyone makes them out to be.

You dont have to be certain youre transgender in order to go on hormones. In fact, Kaylee adds, going on hormones is probably the best way to actually tell if youre trans anyways.

You might have heard that testosterone comes with bad side effects but youll rarely hear them mentioned here. YouTube and Insta gurus are about fun, and increased risks of various cancers and prophylactic hysterectomy are certainly not that. The most common side effect of testosterone that gurus talk about is the one that burnishes their trans bona fides: pain. The pain is acknowledgedeven conveyed with relish. Like a barefoot dash across fiery coals, braving the agony of an intra-muscular injection proves youve moved beyond playing dress-up. You really are trans. And youre not messing around.

So basically I lay down on this little chair thing, with my butt hanging out, an obviously female Alex Bertie vlogged at age seven- teen, documenting her first injection of testosterone. A nurse shoves a needle in, and Im kind of like, Uh, uh, that hurts a little bit more than I thought it would. There was like a spike of pain. And then as she injects it, the pain kind of like goes up a little bit, just slowly increasing. Alex Bertie was more than up to the test: Im not going to lie, it hurt. It f*ing hurt.

But you cant join a church without a baptismcant claim to be blood brothers unless you spill a little blood. This is the trans bar mitzvah, and it is joyously undertaken. Pain is proof of commitment to the cause. Obviously its a bearable pain and completely worth it, Alex Bertie reassures his viewers, before exclaiming, Yeah, Im on testosterone! . . . Im not pre-T anymore! You can almost hear him address his YouTube congregation: Today, I am a man.

Abigail Shrier is a frequent contributor to the Wall Street Journal. She holds an A.B. from Columbia College, where she received the Euretta J. Kellett Fellowship; a B.Phil. from the University of Oxford, and a J.D. from Yale Law School.

View original post here:
Testosterone: The Miracle Drug That Could Solve All Your Problems - The Federalist

MOVIE REVIEW

THE OUTPOST

Rated R. On Amazon, VUDU, iTunes Apple TV and other VOD platforms.

Grade: B

Among the subdivisions of the war movie is the Alamo-theme, in which soldiers usually hopelessly outnumbered trying desperately to stay alive, defend an indefensible position (often in an indefensible war) and even triumph against incredible odds. Among such films that we have seen are, of course, John Waynes unabashedly patriotic The Alamo, the Korean War-set Pork Chop Hill, the magnificent and horrifying German film Stalingrad, and the Mel Gibson-fronted Vietnam War movie We Were Soldiers.

Now, we have Rod Luries The Outpost, a drama about the Oct. 2009 Battle of Kamdesh, when 300 heavily armed Taliban fighters descended, literally, upon an American outpost in the Hindu Kush named Combat Outpost Keating. The film is based on the non-fiction book The Outpost: An Untold Story of American Valor by CNN Washington correspondent Jake Tapper. The action starts before the battle. First Lt. Benjamin Keating (Orlando Bloom, whose British accent does a jack-in-the-box) is the camp commander until he is not and replaced. One of the soldiers, maybe Staff Sgt. Ty Carter (Caleb Landry Jones, whom I have resisted, but he is great in this), points out that the outpost has a serious problem in terms of defensibility. It sits in a spot encircled by foothills that look down upon it. In other words, the outpost gives enemies the upper hand by giving them the higher ground. What idiot said build an outpost here? Can we have him court-martialed retroactively?

Scott Eastwood in 'The Outpost.'

Caleb Landry Jones in 'The Outpost'

For the first hour or so, The Outpost is your average war movie, waiting for the real action to start. Soldiers speak in the cynical, profanity-laden language of the military at war. Dont think about your wives, newcomers are advised. Staff Sgt. Clint Romesha (Scott Eastwood) is the most natural leader. Soldiers express love for one another. Grunts burn trash and complain about how theyre going to get cancer from it, and they are probably right. Every now and then, bullets rain down upon Camp Keating. The Americans return fire, but its hard to see behind the rocks and ridges. Eventually, mortar operators in the pit loft a powerful, accurate round at the enemy insurgents and the firing stops.

Israeli-born, West Point graduate Lurie (The Last Castle, the misguided Straw Dogs remake) makes films heavy on testosterone, even when theyre female-fronted. But his dialogue is usually smarter than the war-movie cliches we hear in this film (Tappers book was adapted by Eric Johnson and Paul Tamasy of Patriots Day). The officers have meetings with village elders, who will turn out to be mostly treacherous. One of the elders points out to the officers that the English, Russians and Americans invested 40 years and incalculable wealth into subduing Afghanistan and have failed.

But when the actual battle begins, The Outpost becomes a beautifully made, utterly terrifying and exhilarating war movie. Like the first 20 minutes of Saving Private Ryan, this is the best part. Seeing what these brave young men will do to save their fellow soldiers under a hail storm of bullets and explosives is stirring.

The film oversells its case when it tells us about the medals won by these soldiers, many of them posthumously. Yes, they fought and died with valor. But in the end, The Outpost is like Catch-22 without the laughs or the ever-more relevant insights about war.

(The Outpost contains extreme, war violence, profanity and lewd language.)

See the original post:
The Outpost latest installment of war as hell - Boston Herald

Johnson was inspired by an Asbury Park Press forum to file a police reform bill passed Monday. Video courtesy of the Assembly Majority Office. Asbury Park Press

FREEHOLD A former Deal police officer has pleaded guilty to witness tampering,Monmouth County Prosecutor Christopher J. Gramiccioni announced.

In a virtual court proceeding Thursday, Joseph Ammaturo, 38,a 14-year veteran of the Deal Police Department,admitted to tampering with a witness regarding a pending narcotics investigation in December 2018.

During the proceeding, Monmouth County Superior Court Judge David Bauman ordered that Ammaturoforfeit his position as a police officer in the Borough of Deal. Since his arrest, Ammaturo hadbeen suspended without pay.

Ammaturo must also forgo all future public employment in New Jersey.According toDataUniverse, the online public database of the Asbury Park Press, Ammaturoreceived an annual salary of $124,316 in 2018.

Press on your side:Gov. Murphy signs police reform inspired by APP that stops bad cops secretly switching jobs

Autoplay

Show Thumbnails

Show Captions

We will continue to hold law enforcement officers accountable for their actions. Bad cops will be weeded out as their illegal actions or infidelity of the public trust are discovered. Mr. Ammaturo can never hold public office in New Jersey ever again that, coupled with probation, is an appropriate sentence," Gramiccioni said in a statement.

The trusted place to find the best home service providers. Find local pros.

"The community expects better of a law enforcement officer, and the law enforcement community holds its own officers to a higher standard," the statement continued. "Mr. Ammaturo failed us all."

Watchdog journalism:NJ lawmakers pass bill inspired by APP to stop bad cops sneaking between jobs

Monmouth County Prosecutor Christopher Gramiccioni.(Photo: File photo)

Ammaturowas arrested at his home in Long Branch on Dec. 19, 2018. He was initiallycharged with witness tampering, conspiracy to possess cocaine and possession of less than 50 grams of suspected marijuana.

In July 2019, Ammaturo was chargedwith possession of clenbuterol, possession of clenbuterol with intent to distribute, distribution of clenbuterol andpossession of testosterone cypionate and doxycycline.

Earlier:Deal cop charged with drug offenses and witness tampering

Intended to used only as a veterinary drug to treat asthma in horses, clenbuterol is unlawfullyingested by some bodybuilders and athletesto increase lean muscle mass and reduce body fat, according to the Drug Enforcement Administration.

Testosterone cypionate is used to treat low testosterone in men a common symptom in performance-enhancing drug use, according to theNational Institute on Drug Abuse. Doxycycline is an antibiotic used to treat bacterial infections, such as chlamydia, according to the Food & Drug Administration.

Police misconduct:Questions swirl around Deal cop's arrest

Any violations of the law and betrayal of the publics trust will not be tolerated by the members of the Deal Police Department, Deal Police Chief Ronen Neuman said in a statement.

We will not allow the actions of this officer to tarnish the commitment and integrity of the men and women of this department. Our officers are highly trained and dedicated professionals that serve with honor, dignity, and respect. The public should be reassured that as an accredited agency our officers are held accountable in both upholding and enforcing the laws.

The Prosecutors Office has connected Ammaturo'scase tothe arrest of an Ocean Township police officer on Feb. 19.

Ryan L. Vaccaro, of Allenhurst, was also charged with possession of clenbuterol, possession of clenbuterol with intentto distribute and distribution of clenbuterol. Previously, he served as president of Police Benevolent Association Local 57 the township police union.

Investigation:Deal cop disciplined after bitter Ocean Township Little League election

Investigators discoveredthatVaccaro provided Ammaturo withthree boxes of clenbuterol that contained about 150 pills. Ammanturothen distributed two of the boxes to other individuals and kept the third box for himself at his home which was later recovered by the investigators, according the Prosecutor's Office.

Ammaturo is scheduled to return for sentencing on Sept. 4. He faces an additional period of probation in addition to his forfeiture of employment.

The case is being prosecuted by Monmouth County Assistant Prosecutor Melanie Falco, Director of the Offices Professional Responsibility and Bias Crimes Unit.

Contributing: Kathleen Hopkins and Erik Larsen

Jai-Leen James is a digital producer at the Asbury Park Press. She can be reached at jtjames@gannett.com or onTwitter @j_james17.

Read or Share this story: https://www.app.com/story/news/crime/2020/07/03/deal-ex-cop-pleads-guilty-witness-tampering-police-misconduct/5371520002/

See original here:
Deal ex-cop pleads guilty to witness tampering in narcotics investigation - Asbury Park Press

3 Penny Stocks Powering Into The Weekend

With the long holiday weekend, penny stocks are sure to be on the list of things to look for. The fact is that weve seen a huge uptick in retail trading of small- and micro-cap stocks recently. So it seems fitting to look for a few of these stocks under $5 while theres plenty of down-time to research.

Overall, the stock market has been extremely volatile. No matter what you think of geopolitics, the price of gold, or the recent stimulus money, this market is trying to aggressively recover. Hopes are high that the economy can continue reopening. However, theres no denying the coronavirus has wreaked havoc on a clear action plan.

Some states and cities are slowly reopening in phases while others are walking back due to new cases. Hospitals in at least two Texas counties are at full capacity heading into the holiday weekend. Reports cite that county judges are urging residents to shelter in place.

Read More

Meanwhile, new curfew orders are back in force in cities like Miami as well. For some people, theyre listening to mixed messages from Washington and theyre deciding they dont need to wear a mask, Miami Beach Mayor Dan Gelber told Fox News Neil Cavuto in an interview on Cavuto Live, Saturday.

What will this mean for markets on Monday? As weve all come to know and love, the trends tend to go by the day. So, depending on how investors digest the information over the weekend, that will likely dictate the opening scene next week. Regardless of coronavirus, weve seen many penny stocks to buy and sell heading into the weekend. Many of these hadnt seen trading momentum like this in months.

But again, weve got a whole new group of retail traders driving markets right now. Theyre more focused on trading volume than on the companies themselves. We saw this, first hand, with companies like Hertz and JC Penney, both of which filed for bankruptcy earlier this year. Yet their share prices soared for a brief moment as gun-slinging traders bought into hype-fueled action. With this in mind, its important to have a plan of action going into your trades next week and in the future.

Blinding going in on a trade just because YOLO isnt the best way to become consistently profitable. Understand the risks involved, set your sites on profit targets, and keep in mind whats driving momentum. Whether its news or plain market hype, youll be well-equipt to make money with penny stocks when you know why theyre moving the way they have.

Lipocine Inc. (LPCN Stock Report) has been in recovery mode this year. If you remember back in February when we started following LPCN stock more closely, the company was still licking its wounds from a huge miss from its TLANDO treatment. The oral testosterone product candidate for testosterone replacement therapy didnt meet 3 endpoints in its study. That was when LPCN stock dropped from over $2.80 to under $0.40.

[Read More] 4 Biotech Penny Stocks To Watch After Key Updates This Week

Fast-forward to the second quarter and the company has been working on advancing its pipeline further. In May Lipocine received RDA clearance for an investigational new drug application for a Phase 2 study of LPCN 1148. This is a prodrug of bioidentical testosterone to treat liver cirrhosis. Furthermore, the company reported results of a preclinical study of its LPCN 1144 which demonstrated encouraging results according to the company. H.C. Wainwright took notice of these milestones and increased its price target on LPCN stock to $3 while maintaining a Buy rating.

But since then, there hasnt been much from the company as far as news is concerned. The last filing that was made in June was an 8-K showing results from its shareholder meeting. Also, if you take a close look youll see that theres been some insider buying going on in June. A number ofFORM 4s filed, show that directors were buying stock last month.On July 2, LPCN stock began trading higher late in the afternoon without any apparent catalyst. However, shares have steadily climbed since late February. Since the 24th, LPCN is up over 160%.

Its exciting when you get to see a company evolve from very little into something much greater. In my opinion, we have been following Waitr Holdings (WTRH Stock Report) since its early day. What was more of a skeptical play on Uber Eats or Postmates has actually evolved into a story that investors have gotten behind. Thats especially true as stay at home orders boosted attention on food delivery companies.

Last November was when we really began digging into the driving force behind Waitr Holdings. Shares had just reached 52-week lows and there were more questions than answers as to the future prospects of the company. However, as fait would have it, management sunk its teeth into the company identified that it was lax in its efforts and focused on building the business moving forward.

Specifically, Adam Price, CEO at the time said, Moving forward, you should expect to see steady improvements in cash flow compared to the past several quarters. You should also expect to see a refocus on existing markets where there is a strong user base, great brand awareness and still a lot of growth potential.

As many have seen WTRH stock has been steadily on the move ever since. Most recently, Waitr announced that it would be expanding its Louisiana footprint. The company hired a total of 225 customer service and dispatch team members in the state since January. Furthermore, after Carl Grimstad took over at Waitr in January 2020, the company has implemented strategic initiatives around service and profitability. These initiatives along with others have led to improved revenue and Waitrs first ever profitable month in February of this year.

Cinedigm Corp (CIDM Stock Report) has also benefited from mandates during coronavirus quarantine. June was a big month for CIDM stock and to be honest, the big move we discussed on June 3, could have easily been a case of the 1-day penny stock breakouts. But that move continued even higher the next day. At the time we started following the stock, CIDM shares traded around $0.75. It had already enjoyed a jump in May and like most illiquid stocks (at the time) expectations werent extremely high for a continuation. But as we know, Genius Brands breakout this year had traders looking for sympathy plays & Cinedigm may have initially been one of them.

Cinedigm acquired all North American distribution rights to Cotton Films EVERYDAY MIRACLES in late-May. Following this, the company announced a strategic partnership with SpringServe, the leading ad serving platform for over-the-top and connected TV. It also expanded its distribution of The Bob Ross Channel on Roku (ROKU Stock Repor). What added more fuel to the fire a partnership with Vewd. According to Cinedigm, Vewd is the worlds largest Smart TV over-the-top provider and will now offer Cinedigms portfolio of entertainment networks. But following these big updates, CIDM stock has been free-falling a bit. After reaching $6, shares pulled back as low as $1.67 last week.

[Read More] Is The US Government Investing In Penny Stocks? $700M Could Say Yes

Before the holiday weekend went underway, however, CIDM stock started rebounding late Thursday afternoon. This came after the company announced its next earnings date. Cinedigm reports Q2 figures on July 6th. So if this is one of the names on your list of penny stocks right now, keep this in mind. Speculative momentum can be a factor going into earnings. But the devils in the details. A positive result may bode well for the market but as weve seen, lackluster earnings can put a damper on short-lived bullishness.

Original post:
Will These Penny Stocks Bring Fireworks After The 4th? - Penny Stocks

A new research report released by MarketsandResearch.biz with the title Global Testosterone Cypionate Injection Market Growth 2020-2025 covers the overall analysis of the market, detailing information about key players, sales, future trends, research findings, and current and future opportunities during 2020 to 2025 forecast period. The report significantly identifies the qualitative influence of various market factors on market segments and geographies. The report defines, segments the global Testosterone Cypionate Injection market and encompasses market potential, influential trends, and issues facing the market. The report categorizes segments the market on the basis of product type, application, technology, and region.

Market Rundown:

To offer more clarity regarding the industry, the report takes a closer look at the current status of different factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries. In the end, the report makes some important proposals for a new project of Testosterone Cypionate Injection market before evaluating its possibility. The report includes factors like industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The study offers business owners, stakeholders, and field marketing personnel with a significant evaluation of other factors such as demand and supply status, import and export, distribution channel, consumption volume, and production capability.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/59758

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Testosterone Cypionate Injection market.

The market report covers the following companies: Cipla, Hikma, Pfizer, Sun Pharma, Perrigo, Paddock Laboratories, Genesis Pharmaceuticals, Meditech Pharmaceutical, Perrigo,

Market segment by product type, along with their consumption (sales), market share and growth rate includes: 100mg/ml, 200mg/ml,

Market segment by application, along with their consumption (sales), market share and growth rate covers: Hospital, Clinics, Recovery Center,

Furthermore, thoughts and opinions from companies and individuals in the report who are unbiased and less emotionally attached to recent developments, products, or services are listed in the report. Industry experts conducting the study further estimate the potential of the global Testosterone Cypionate Injection industry. According to the analysts, this information is important for firms looking to launch an innovative service or product on the market.

Market Segmentation By Region:

Further, in the report, analysis of the regional market information is covered by separating major different regions as, Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries). It focuses on analyzing the geographical subdivisions of the global Testosterone Cypionate Injection market based on factors such as key regions, with production, consumption, revenue (million USD), and market share and growth rate of the market.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/59758/global-testosterone-cypionate-injection-market-growth-2020-2025

The Study Aims Are:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

See original here:
Global Testosterone Cypionate Injection Market 2020 | Top Leading Countries, Consumption, Trends, Revenue, Challenges and Global Forecast 2025 - Galus...

The global Testosterone Replacement Therapy market was valued at xx million in 2019 and is projected to reach US$ xx million by 2026, at a CAGR of xx during the forecast period. While the Testosterone Replacement Therapy market size in US was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4765452

The Testosterone Replacement Therapy manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.

This information is crucial from the point of view of businesses looking for investments, new ventures, mergers and acquisitions and seeking more valuable and insightful information on markets of their interests. It provides readily available research reports and also cost-effective customized research conducted by their team of experts.

Further, the report presents profiles of competitors in the market, including the following:

AbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa Kirin

Browse the complete report @ https://www.orbisresearch.com/reports/index/testosterone-replacement-therapy-market-in-india-manufacturing-and-consumption-outlook-and-forecast-2020-2026

This report on Testosterone Replacement Therapy also gives an analysis of the market segments based on applications, types and key players. It consists of an elaborate chapter on the competitors dwelling in the Testosterone Replacement Therapy market. Company profiles consists of information on company history, achievements and future plans. All this information gives a better understanding of how the Testosterone Replacement Therapy market has evolved so far. Such kind of information also sets a benchmark for new companies venturing out in new markets.

For effective analysis, the report has considered the period from 2020 2026 as the forecast period. Based on the detailed historical data an analysis for the forecast period is created. Every market research study is based on a methodology which helps segment out the market in a way where every aspect is focused in detail. This report on Testosterone Replacement Therapy is also based on a research methodology which talks about all the essential aspects of the market. One of the most important factors of any market intelligence report is the study of the regions where the market has evolved so far and is expected to evolve further. In this report, the key regions focused on are the US, Europe, China, Japan and India regions.

By Type

GelsInjectionsPatchesOther

By Application,

HospitalsClinicsOthers

The Testosterone Replacement Therapy report also contains a thorough SWOT analysis of the market giving special emphasis to strengths, weaknesses, opportunities and threats the market holds. The report concludes with exclusive comments and insights from industry experts from the market.

To make an enquiry on [emailprotected] https://www.orbisresearch.com/contacts/enquiry-before-buying/4765452

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199 ; +91 895 659 5155

Read the original:
Testosterone Replacement Therapy Market in India-Manufacturing and Consumption, Outlook and Forecast 2020-2026 - Cole of Duty

Global Testosterone Replacement Therapy Market Report, Sales and Consumption Status and Prospects Professional Research, the report classifies the global Testosterone Replacement Therapy Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

Testosterone Replacement Therapy Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a Global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Testosterone Replacement Therapy market between 2020 and 2027. In terms of value, the Testosterone Replacement Therapy industry is expected to register a steady CAGR during the forecast period.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/2024

The key players profiled in this report include: AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer, Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Global (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of Testosterone Replacement Therapy

o The micro-level analysis is conducted based on its product types, end-user applications, and geographie

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Testosterone Replacement Therapy market

Table of Contents

Report Overview: It includes the Testosterone Replacement Therapy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Testosterone Replacement Therapy market trends and shares, market size analysis by region and analysis of Global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Testosterone Replacement Therapy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Testosterone Replacement Therapy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2024

The research study can answer the following Key questions:

Major Highlights of TOC:

Chapter One: Global Testosterone Replacement Therapy Market Industry Overview

1.1 Testosterone Replacement Therapy Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Testosterone Replacement Therapy Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Global Testosterone Replacement Therapy Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Testosterone Replacement Therapy Market Size by Demand

2.3 Global Testosterone Replacement Therapy Market Forecast by Demand

Chapter Three: Global Testosterone Replacement Therapy Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 Testosterone Replacement Therapy Market Size by Type

3.3 Testosterone Replacement Therapy Market Forecast by Type

Chapter Four: Major Region of Testosterone Replacement Therapy Market

4.1 Global Testosterone Replacement Therapy Sales

4.2 Global Testosterone Replacement Therapy Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/2024

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

**Be Safe and Stay Home**

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.ShahPhone: US +1-206-701-6702/UK +44-020 8133 4027[emailprotected]

Read more here:
Testosterone Replacement Therapy Market Shows Expected Trend and Forecast to 2027 | Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin...

The most common congenital disorders of all, especially in baby boys, are differences in a newborns sexual anatomy that is not standard female or male. In boys, they include undescended testicles, misplaced urethras, and improperly developed internal organs.

Some of these disorders may be treated with surgery and some also with hormonal supplementation. Scientists are troubled because the incidence of these disorders is increasing, especially in developed countries. While causes are unknown, researchers suspect that endocrine disruptors from environmental contaminants may be involved.

Joan Jorgensen

Its hard to know how something goes wrong if you dont know how it goes right, says Joan Jorgensen, a professor of comparative biosciences in the University of WisconsinMadison School of Veterinary Medicine.

So, Jorgensen, lead author Anbarasi Kothandapani, and others have set out to understand how functional reproductive systems are formed. Over several years, they studied how one gene, GLI3, coordinates the precisely timed development of the male reproductive organs. Using a mouse model, they discovered that GLI3 promotes the growth of the only cells capable of producing male hormones in a fetus. Without enough of those cells, development goes awry.

The researchers published their findings June 4 in the journal PLOS Genetics. Their works helps us understand how genes and hormones interact to develop male reproductive systems, a step toward researching why disorders in these organs have become more common and how we might prevent them.

The Jorgensen lab has long studied male and female sex differentiation in developing mice. Altogether, a male fetus must successfully have testes descend toward the scrotum, differentiate external genitals, and develop internal organs such as the prostate. Much of this process is controlled by a genetic pathway whimsically named Hedgehog after the gene was discovered in flies covered in bristles and hormones. The two most important hormones are testosterone and another named INSL3.

The GLI3 gene is part of the Hedgehog gene pathway and mutations in the gene are linked to reproductive tract disorders in humans. To study how GLI3 works, the Jorgensen lab turned to a line of mice carrying a mutation that models human mutations in the gene. In mice, the mutation is lethal before birth, so they had to study its effects in developing embryos.

The first thing we wanted to do was see if they had the same reproductive organ phenotypes as human patients, says Jorgensen. These problems include undescended testicles and disorders in urethra placement.

The mutant mice had several defects similar to humans with mutations in the gene. They experienced delays in the descent of their testicles within their abdomens And in about half of the mutants, the urethra opened at the base of the penis instead of at the tip.

Suspecting a problem with the hormone-producing cells called Leydig cells, the researchers examined the testes. Although mutant mice had typical-looking gonads, Jorgensens team saw their testes had fewer Leydig cells and these cells even grew weaker as the embryos developed.

We concluded that the cells started off okay, but they werent able to maintain their identity and they lost their function, says Jorgensen. Over time, they werent able to increase the amount of androgen synthesis needed to make sure everything develops properly.

The researchers discovered that the Hedgehog pathway, through GLI3, stimulates the formation of Leydig cells, which produce the hormones necessary to develop male sex organs. And those hormones go on to reinforce the Hedgehog pathway, which is vital for developing the prostate and penis. They concluded that most of the defects in the mutant mice could be explained by dysfunctional Leydig cells.

Treating pregnant mice with extra testosterone wasnt enough to correct all the defects, because the GLI3 gene was itself necessary, especially for producing a normal penis. But when the researchers reintroduced the non-mutant GLI3 gene into the mutant testes in culture, they were able to restore production of genes necessary for the production of testosterone.

The upshot is that researchers discovered a complex dance between genes and hormones. Any misstep in the waltz can spell disaster.

There are several environmental disruptors out there that will impact the Hedgehog pathway. When you put that together with genetic mutation, it could make some individuals more susceptible to developmental disorders than others, says Jorgensen.

This improved clarity in how the genes are supposed to function could help researchers understand how environmental toxins might be to blame for a rise in sex development disorders. That understanding is the first step toward prevention.

This work was supported in part by the National Institutes of Health (grants R01HD075079, R01- HD090660, R01-HD090660-S, R01-AR070093, R01-DK110408, and U01-DK110807).

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

Read more:
Forming genitals in boys requires complex dance between genes and hormones - University of Wisconsin-Madison

In the last decade, diagnosis of gender dysphoria severe discomfort in ones biological sex has exploded across the West.

Between 2016 and 2017, the number of gender surgeries for natal females in the US quadrupled; in the UK, the rates of gender dysphoria for teenage girls are up 4,400 percent over the previous decade. An ailment that typically began in early childhood, and overwhelmingly afflicted males, suddenly has a new dominant demographic: teenage girls.

In 2016, Brown University public health researcher Lisa Littman was scrolling through social media when she noticed that a group of teen girls from her small town in Rhode Island all from the same friend group had come out as transgender.

Intrigued by the statistical unlikelihood, Littman began to study the phenomenon and, in 2018, published the results. She hypothesized that transgender identification had become one more peer contagion among adolescent females. Anxiety-ridden, middle-class girls who once engaged in cutting or anorexia were now wearing binders (breast-compressing undergarments), taking testosterone and undergoing voluntary double mastectomies

I have interviewed over four dozen families whose teen daughters became caught in this current. Their stories follow a pattern: A girl never expresses any discomfort with her biological sex until puberty, when anxiety and depression descend. The girl struggles to make friends. She immerses in social media and discovers transgender gurus. Or her school holds an assembly celebrating gender journeys, or hosts a Gay-Straight Alliance club pushing gender ideology. At first, she tries out a new name and pronouns. Her school encourages her, keeping all this a secret from her parents. Then, she wants more.

So many women were once tomboys, as I was inhabiting femininity itchily, like the floral dress your mother made you wear. But tomboy doesnt exist anymore, as any teenage girl will tell you. In its place is an endless litany of gender categories, from agender to non-binary, gender fluid to trans. Imperfectly feminine girls are encouraged to consider their options.

As author J.K. Rowling recently wrote in a blog post that caused an uproar (but had many women nodding their heads): If Id found community and sympathy online that I couldnt find in my immediate environment [as a teen], I believe I could have been persuaded to turn myself into the son my father had openly said hed have preferred.

Ive spent the last year meeting transgender adults, trans-identifying teens and their parents, as well as experts in gender dysphoria, gender therapists, public school teachers, gender surgeons, endocrinologists and detransitioners young women who medically transitioned to the opposite sex, only to regret it.

While studies of detransitioners are only now being done, and numbers are hard to obtain, the detrans group on Reddit has nearly 13,000 members.

One detransitioner, Desmond, said her use of testosterone brought on severe uterine pain and necessitated a hysterectomy. No one really helped me at that point, she said. They were so easy to the pushing of hormones, of putting the thought of surgery in my head, of Yes, this will make you happier, this will make your life easier, this will get rid of your depression, this will help you become your true self rather than treating it as a way of escaping myself before really coming to terms and finding my true self again.

Our culture has both made womanhood less appealing and also greased the skids toward social and medical transition for confused teens in genuine pain. Public schools peddle gender ideology with a fervor that would make a preacher blush. Transgender social-media gurus tout the euphoria testosterone produces, and Planned Parenthood is one of the largest suppliers of testosterone and they do apprise of the risks, but on an informed consent basis. (Meaning, no therapist note is required and you leave the clinic with a very serious drug based essentially on the patients self-diagnosis.) Hundreds of plastic surgeons are happy to offer medically unnecessary double-mastectomies to girls as young as 16 without so much as a therapists note.

Teens today spend far less time in person with friends than any previous generation. Most of their social life occurs online, where feelings of inadequacy run wild and the challenge of making and keeping friends never lets up. One of the surest ways to win friends and followers is by declaring a glamorous new gender identity, and so they do. Anything to feel lonely no more.

But for many of these girls, the new identity provides no cure. The distress that catalyzed their gender journeys remains. There is no hack for adolescence. We push and scream through its blinding confusion because there is no choice but to grow up.

Abigail Shrier is the author of Irreversible Damage: The Transgender Craze Seducing Our Daughters (Regnery), out Tuesday.

Excerpt from:
How 'peer contagion' may play into the rise of teen girls transitioning - New York Post

Unfortunately, Angie, you've got plenty of company. Polycystic ovarian syndrome, or PCOS, is a condition that affects up to 1 in 10 women of child-bearing age. In a nutshell,PCOSis characterized by hormonal imbalances, involving not just the reproductive hormones (like estrogen and testosterone) but also hormones that regulate blood sugar, fat storage, and appetite.

Symptoms of PCOS may includepainful or irregular periods, acne, abnormalhair growth, increased appetite, weight gain, and difficulty losing weight. Women with PCOS often develop metabolic syndrome, which increases your risk of heart disease and diabetes. And the reverse is also true: Women with metabolic syndrome are more likely to develop PCOS. PCOS is also a leading cause of infertility.

PCOS is strongly linked with obesityand as obesity levels have risen, PCOS has become a more common diagnosis. But there are also lean women who suffer from PCOS. Almost all women with PCOS, however, have some degree of insulin resistance, which is also known as pre-diabetes.

Thefirst-line therapy for PCOSis a diet and lifestyle makeover with the primary goal of improving the bodys sensitivity to insulin. Here are 3 ways to start on a virtuous path.

Tip #1: Lose weight (if you need to)

Weight loss improves insulin sensitivity and you dont necessarily have to reach your goal weight to get this benefit. Even a modest amount of weight loss can begin to reverse symptoms of PCOS. For example, if you are 50 pounds overweight, losing 10 pounds can make a big difference in your PCOS symptoms, even though you might still be significantly overweight.

Above all, you want to lose weight at a pace you can maintain long-term. Crash diets that produce fast weight loss followed by the inevitable rebound weight gain do more harm than good.

Tip #2: Be more active

Exercise is also a great way to improve insulin sensitivity. It also helps rebalance reproductive hormones. As a bonus, it can also help with weight loss. A combination of aerobic exercise (anything that gets your heart rate up for 30 minutes a day) and strength training will work best.

Tip #3: Eat regularly but not too frequently

Although some people claim thateating every 2-3 hoursis ideal,spacing your meals outmore can help improve insulin sensitivity. Instead of having a small meal or snack every few hours, try to get used to eating a more substantial meal and then waiting 4-5 hours before eating again. For tips on how to choose foods that will keep you full longer, review my episodes onsatiationandsatiety.

Continue reading How to Fight PCOS with Diet and Nutrition on QuickAndDirtyTips.com

View original post here:
How to Fight PCOS with Diet and Nutrition - Scientific American

Page 52«..1020..51525354..6070..»

Home » Testosterone » Page 52